Patents Assigned to The University of Chicago
-
Patent number: 12291738Abstract: The present disclosure is directed to methods and/or uses of oligonucleotide conjugates for assays and flow cytometry detections and related systems and/or kits. Certain methods are directed to a method for detecting one or more biological targets of a sample in a detection assay, comprising: providing a molecular probe, comprising a binding moiety and an oligonucleotide sequence, to a sample comprising one or more biological targets; binding the one or more biological targets with the binding moiety; providing a detectable component to the sample, wherein the detectable component comprises a signal generating moiety conjugated to an oligonucleotide sequence complementary to the oligonucleotide sequence of the molecular probe; hydridizing the oligonucleotide sequence of the target-bound molecular probe to the detectable component; and detecting a signal generated from the hydridized detectable component. Various other embodiments, applications etc. are disclosed herein.Type: GrantFiled: July 7, 2021Date of Patent: May 6, 2025Assignees: The University of Chicago, EMD Millipore CorporationInventors: David A. Schwartz, Jimmy Williams, Xinfang Zhao, Chunfang Zhao, William B. Busa, Stephen J. Kron, Amy Catherine Flor
-
Patent number: 12292893Abstract: A radiology workstation (24) includes at least one display component (30, 32); at least one user input device (28); and at least one microprocessor (26, 34) programmed to generate a contextual ranking of clinical codes for a context received via the at least one user input device (28) and to display information pertaining to the contextual ranking on the display component (30, 32) of the radiology workstation (24). The contextual ranking is computed by the microprocessor from (i) statistics of occurrences of the clinical codes in radiology reports contained in a radiology reports database (10) and satisfying the context and (ii) statistics of the clinical codes in problem lists contained in a problem lists database and satisfying the context.Type: GrantFiled: April 4, 2017Date of Patent: May 6, 2025Assignees: Koninklijke Philips N.V., The University of ChicagoInventors: Merlijn Sevenster, Paul Joseph Chang, Amir Mohammad Tahmasebi Maraghoosh
-
Patent number: 12281060Abstract: Disclosed herein is a class of molecules termed remodilins that are effective in treating asthma, pulmonary fibrosis, and associated disorders. The molecules ameliorate asthma and pulmonary fibrosis symptoms by various mechanisms, including inhibiting airway smooth muscle contractile protein accumulation, reducing airway constrictor hyperresponsiveness, inhibiting bronchial fibroblast transformation into myofibroblasts, and/or treating or preventing airway or pulmonary fibrosis.Type: GrantFiled: April 2, 2020Date of Patent: April 22, 2025Assignees: The University of Chicago, The United States of America, as Represented by the Secretary, Department of Health and Human Services, President and Fellows of Harvard College, IIT Research Institute, Beth Israel Deaconess Medical Center Inc.Inventors: Julian Solway, Nickolai Dulin, Diane Luci, David Maloney, Chan Young Park, Jeffrey Fredberg, David McCormick, Ramaswamy Krishnan
-
Patent number: 12280038Abstract: Described herein are novel ?- and ?-propargyl carboxylic acids and esters. The novel compositions are antagonists of CSE and may be used to modulate of the activity of the carotid body, therefore providing therapeutic benefits for sleep-related breathing disorders and related conditions.Type: GrantFiled: June 24, 2022Date of Patent: April 22, 2025Assignees: The University of Chicago, IIT Research InstituteInventors: Michael J. Kates, Nanduri R. Prabhakar, David L. McCormick, Miguel Muzzio
-
Patent number: 12280066Abstract: Embodiments of the invention are directed to methods of determining the prognosis of a breast cancer patient by evaluating the activity of the glucocorticoid receptor in tumor cells. Other embodiment include methods of treating breast cancer cells, particularly, chemo-resistant cells, with a glucocorticoid receptor antagonist and an anticancer agent or compound.Type: GrantFiled: December 15, 2023Date of Patent: April 22, 2025Assignee: The University of ChicagoInventors: Deng Pan, Masha Kocherginsky, Suzanne D. Conzen
-
Publication number: 20250122255Abstract: The current disclosure relates to methods for treating ovarian cancer based on specific antigen expression of the cancer. Furthermore, the expressed antigen may be used in immunotherapeutic methods for treatment of the ovarian cancer. Aspects of the disclosure relate to immunotherapies targeting CT45 polypeptides, methods for treating ovarian cancer based on CT45 expression, and kits for detecting CT45 polypeptides and nucleotides.Type: ApplicationFiled: December 20, 2024Publication date: April 17, 2025Applicants: The University of Chicago, Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V.Inventors: Ernst Lengyel, Matthias Mann, Marion Curtis, Fabian Coscia
-
Publication number: 20250122240Abstract: The present disclosure provides macrocyclic and macrobicyclic peptides with secondary structures that are stabilized over the corresponding non-cyclic peptides. The macrocyclic and macrobicyclic peptides are formed from peptides with adduct-forming, complementary reactive side chain moieties.Type: ApplicationFiled: October 28, 2024Publication date: April 17, 2025Applicant: The University of ChicagoInventors: Raymond E. MOELLERING, Jeffrey E. MONTGOMERY
-
Patent number: 12276710Abstract: A method for quantum spin amplification includes spin-polarizing an ensemble of quantum spins in an initial spin state to generate a transversely-polarized sensing spin state. The quantum spins identically have an upper energy state and a lower energy state. The sensing spin state accumulates a phase shift that transforms the sensing spin state into a phase-accumulated spin state having first and second transverse polarization components. The phase-accumulated spin state is transformed into an intermediate spin state by rotating the first transverse polarization component into a longitudinal polarization component of the intermediate spin state. The ensemble is then coupled to an auxiliary mode, during which the intermediate spin state evolves such that the second transverse polarization component is amplified into an amplified transverse polarization. This amplified transverse polarization is then measured.Type: GrantFiled: November 22, 2022Date of Patent: April 15, 2025Assignee: The University of ChicagoInventors: Aashish Clerk, Martin Koppenhöfer, Peter Groszkowski
-
Patent number: 12276654Abstract: Disclosed, in part, are methods and compositions for evaluating two or more target proteins from the same family through the use of a molecular construct that contains a targeting group and a retrieval tag. The method can, in some aspects, quantify the activity and function of the proteins of interest, visualize active enzymes at the subcellular and intercellular scale, and increase dynamic range via signal amplification.Type: GrantFiled: November 21, 2018Date of Patent: April 15, 2025Assignee: The University of ChicagoInventors: Raymond E. Moellering, Gang Li
-
Publication number: 20250090588Abstract: In aspects, the present disclosure provides a method of treating or preventing premature ovarian insufficiency or polycystic ovary syndrome in a female mammal, the method comprising, consisting essentially of, or consisting of administering to the female mammal an effective amount of (i) mesenchymal stem cells (MSCs) or secretome from MSCs, wherein the MSCs overexpress (a) miR144, (b) BMP-2, (c) TGF?1, (d) IL-10, or (e) any combination of (a), (b), (c) and (d); (ii) exosomes produced by MSCs, wherein the MSCs overexpress (a) miR144, (b) BMP-2, (c) TGF?1, (d) IL-10, or (e) any combination of (a), (b), (c) and (d); and/or (iii) exosomes comprising one or more effectors, wherein the one or more effectors comprises, consists essentially of, or consists of (a) miR144, (b) BMP-2, (c) TGF?1, (d) IL-10, or (e) any combination of (a), (b), (c) and (d), and wherein the amount of the effector per exosome is greater than the amount of the effector per exosome when produced by unmodified MSCs.Type: ApplicationFiled: July 6, 2022Publication date: March 20, 2025Applicant: The University of ChicagoInventors: Ayman Al-Hendy, Hang-Soo Park
-
Patent number: 12240890Abstract: Provided herein are compositions and methods for treating and/or preventing pathogenic fungal infection and for maintenance of microbiome commensalism. In particular, provided herein are compositions comprising modified peptide YY (PYY) peptides and therapeutic and/or prophylactic methods of use thereof.Type: GrantFiled: May 16, 2018Date of Patent: March 4, 2025Assignee: The University of ChicagoInventors: Eugene B. Chang, Joseph F. Pierre, Katharine A. Harris
-
Publication number: 20250064989Abstract: Radioisotope-labeled small molecule activity-based probes that target the cancer associated serine hydrolase neutral cholesterol ester hydrolase 1 (NCEH1) are described. The probes can undergo a reaction with the NCEH1, resulting in covalent bonding of a portion of the probe molecule to the NCEH1. Also described are methods of labeling NCEH1 in biological samples, such as cells or tissue, and methods of visualizing tumors using the radioisotope-labeled NCEH1 probes as tracer compounds, either alone or in combination with assessing the efficacy of a cancer treatment or potential cancer treatment.Type: ApplicationFiled: November 8, 2024Publication date: February 27, 2025Applicant: The University of ChicagoInventors: Raymond E. Moellering, Jae Won Chang
-
Patent number: 12226227Abstract: The present disclosure provides methods for diagnosing and determining the disease progression of neurodegenerative disorders in patients using neurophysiological biomarkers.Type: GrantFiled: November 28, 2022Date of Patent: February 18, 2025Assignee: The University of ChicagoInventors: Naoum P. Issa, Kourosh Rezania
-
Patent number: 12227769Abstract: The current disclosure relates to methods, compositions and kits for detecting modified adenosine in a target RNA molecule. Aspects relate to a method for detecting modified adenosine in a target ribonucleic acid (RNA) comprising contacting the target RNA with an adenosine deaminase enzyme (adenosine deaminase, RNA-specific) to generate a target RNA with deaminated adenosines and sequencing the target RNA with deaminated adenosines; wherein the modified adenosine is detected when the nucleotide sequence includes adenosine within a m6A motif.Type: GrantFiled: October 18, 2019Date of Patent: February 18, 2025Assignees: The University of Chicago, Nationwide Children's Hospital, The Ohio State UniversityInventors: Jianrong Li, Mark E. Peeples, Chuan He, Stefan Niewiesk, Mijia Lu, Miaoge Xue, Zijie Zhang, Boxuan Zhao
-
Publication number: 20250052960Abstract: Systems and methods for generating and manipulating a guided electromagnetic wave in a waveguide are provided. The optical system includes a waveguide, such as a two-dimensional waveguide, and an optical element disposed adjacent the surface of the waveguide. To generate the guided electromagnetic wave, a converging laser beam is generated and coupled to the waveguide by steering the converging laser beam towards an edge of the waveguide and with a beam center trajectory approximately parallel to a surface of the waveguide.Type: ApplicationFiled: August 8, 2024Publication date: February 13, 2025Applicant: The University of ChicagoInventors: Jiwoong Park, Hanyu Hong, Myungjae Lee
-
Patent number: 12186402Abstract: Provided herein are polymer materials that find use in, for example, delivery of short-chain fatty acids. In particular, polymers are provided that form stable nanoscale structures and release their payload, for example, by cleavage of a covalent bond (e.g., via hydrolysis or enzymatic cleavage). The polymers are useful, for example, for delivery of payloads (e.g., SCFAs) to the intestine for applications in health and treatment of disease, and have broad applicability in diseases linked to changes in the human microbiota including inflammatory, autoimmune, allergic, metabolic, and central nervous system diseases, among others.Type: GrantFiled: April 19, 2023Date of Patent: January 7, 2025Assignee: The University of ChicagoInventors: Jeffrey A. Hubbell, Ruyi Wang, D. Scott Wilson, Cathryn R. Nagler, Catherine Plunkett
-
Patent number: 12188084Abstract: Methods, compositions and kits are provided to amplify an amount of genomic methylated DNA that can be subsequently analyzed and/or sequenced. It has particular use with small amounts of DNA, including, but not limited to cell free DNA samples. In some embodiments, the ratio of polymerase and methyltransferase is controlled in order to provide maximum yields. In some embodiments, a dual primase/polymerase is used.Type: GrantFiled: September 27, 2021Date of Patent: January 7, 2025Assignee: The University of ChicagoInventors: Chuan He, Boxuan Simen Zhao, Pradnya Narkhede, Chang Liu, Xiaolong Cui
-
Patent number: 12180267Abstract: Provided herein are anti-neuraminidase agents useful for neutralization of influenza virus infection, and methods of use and manufacture thereof. In particular, compositions comprising anti-neuraminidase agents (e.g., antibodies) that are cross-reactive with multiple influenza strains are provided, as well as methods of treatment and prevention of influenza infection therewith.Type: GrantFiled: June 15, 2023Date of Patent: December 31, 2024Assignee: The University of ChicagoInventors: Patrick Wilson, Yaoqing Chen, Haley L. Dugan
-
Patent number: 12174225Abstract: Methods and systems are disclosed for sensing an environment electric field. In one exemplary implementation, a method includes disposing a sensor in the environment, wherein the sensor comprising a crystalline lattice and at least one optically-active defect in the crystalline lattice; pre-exciting the crystalline lattice to prepare at least one defect in a first charge state using a first optical beam at a first optical wavelength; converting at least one defect from the first charge state to a second charge state using a second optical beam at a second optical wavelength; monitoring a characteristics of photoluminescence emitted from the defect during or after the conversion of the at least one defect from the first charge state to the second charge state; and determining a characteristics of the electric field in the environment according to the monitored characteristics of the photoluminescence.Type: GrantFiled: January 24, 2023Date of Patent: December 24, 2024Assignee: The University of ChicagoInventors: Gary Wolfowicz, Samuel James Whiteley, David Daniel Awschalom
-
Publication number: 20240415851Abstract: Disclosed herein is a class of molecules termed remodilins that inhibit serum response factor (SRF). By inhibiting SRF, a number of downstream pathways can be targeted. The remodilins can be used to treat glaucoma, inhibit tumor cell growth, inhibit tumor metastasis, inhibit hypoxia-induced response, and/or reduce cellular metabolism.Type: ApplicationFiled: March 14, 2024Publication date: December 19, 2024Applicants: The University of Chicago, The United States of America, as Represented by the Secretary, Department of Health and Human, President and Fellows of Harvard College, IIT Research Institute, Beth Israel Deaconess Medical Center, Inc.Inventors: Julian SOLWAY, Nickolai DULIN, Marsha ROSNER, Gokhan MUTLU, Diane LUCI, David MALONEY, Chan Young PARK, Jeffrey FREDBERG, David MCCORMICK, Ramaswamy KRISHNAN